Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 18:59:51 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Alzecure Pharma - Further Pipeline Advancement Expected

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Alzecure Pharma - Further Pipeline Advancement Expected

2021-03-04 11:35:00

Alzecure Pharma’s Q4’20 report (published last week) summarized a year where the company advanced across its pipeline and reported milestones according to plan. Even though we see no major milestones (except a partner deal that serves as a joker for this exciting early-stage biotech) occurring in 2021, it will be equally important to continue steady progress and its transition into a fully-fledged development organization. In this update, we deep-dive onto the news flow investors could expect and go through the key changes we have made that have led to a new Base Case.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/